These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18377341)

  • 1. Pharmacoeconomics of linezolid.
    Grau S; Rubio-Terrés C
    Expert Opin Pharmacother; 2008 Apr; 9(6):987-1000. PubMed ID: 18377341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
    López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
    Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.
    Vinken A; Li Z; Balan D; Rittenhouse B; Wilike R; Nathwani D
    J Hosp Infect; 2001 Dec; 49 Suppl A():S13-24. PubMed ID: 11926436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.
    McCollum M; Rhew DC; Parodi S
    Clin Ther; 2003 Dec; 25(12):3173-89. PubMed ID: 14749155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M; Sorensen SV; Liu LZ
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms.
    Grau S; Mateu-de Antonio J; Soto J; Marín-Casino M; Salas E
    Pharm World Sci; 2005 Dec; 27(6):459-64. PubMed ID: 16341954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Lyles A
    Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M; Hsu DI
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstein R
    Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain.
    Grau S; Aguado JM; Mateu-de Antonio J; Gonzalez P; Del Castillo A
    J Chemother; 2007 Aug; 19(4):398-409. PubMed ID: 17855184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
    Machado AR; Arns Cda C; Follador W; Guerra A
    Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
    Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2005; 23(9):945-64. PubMed ID: 16153136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.
    Nathwani D; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Tavakoli M; Tang T
    Int J Antimicrob Agents; 2004 Apr; 23(4):315-24. PubMed ID: 15081078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.
    Nathwani D; Barlow GD; Ajdukiewicz K; Gray K; Morrison J; Clift B; France AJ; Davey P
    J Antimicrob Chemother; 2003 Feb; 51(2):391-6. PubMed ID: 12562708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M; Nathwani D; Dryden M
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
    Patanwala AE; Erstad BL; Nix DE
    Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.